|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select publications
Buzdar A et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial. Lancet Oncol 2006;7(8):633-43. Abstract
Coates AS et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 2007;25(5):486-92. Abstract
Coombes RC et al; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081-92. Abstract
Cuzick J et al. Optimal use of aromatase inhibitors for adjuvant treatment of hormone-sensitive early breast cancer: Up front or sequenced after tamoxifen? Proc ASCO 2007a;Abstract 541.
Cuzick J et al; International Breast Cancer Intervention Study I Investigators. Long-term results of tamoxifen prophylaxis for breast cancer — 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007b;99(4):272-82. Abstract
Cuzick J et al; IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial. Lancet 2002;360(9336):817-24. Abstract
Duffy S, on behalf of the ATAC Trialists’ Group. Anastrozole is associated with a lower risk of endometrial abnormalities than tamoxifen: First report of the ATAC trial endometrial sub-protocol at 6 years follow-up. San Antonio Breast Cancer Symposium 2006;Abstract 4055.
Duffy SR et al. Gynecologic interventions during adjuvant therapy with anastrozole or tamoxifen: Results from the ATAC trial. San Antonio Breast Cancer Symposium 2005;Abstract 2056.
Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97(17):1262-71. Abstract
Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract
Kennecke HF et al. Late risk of relapse and mortality among postmenopausal women
with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol
2007;18(1):45-51. Abstract
 |
 |
EDITOR
Neil Love, MD
INTERVIEWS
Sharon Giordano, MD, MPH
- Select publications
Rowan T Chlebowski, MD, PhD
- Select publications
Tumor Panel Case Discussion
- Select publications
INTERVIEWS (continued)
Jack Cuzick, PhD
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
